NCT03723811View on ClinicalTrials.gov

Clinical Study to Investigate the Efficacy and Safety of SJP002 Ophthalmic Solution in Patients With Dry Eye Syndrome.

PHASE2CompletedINTERVENTIONAL

Enrollment

152

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

June 26, 2018

Study Completion Date

June 26, 2018

Conditions

Dry Eye Syndromes

Interventions

DRUG

SJP002 BID

1 drop b.i.d for 12 weeks

DRUG

SJP002 QID

1 drop q.i.d for 12 weeks

DRUG

SJP002 Placebo 1

1 drop q.i.d for 12 weeks

DRUG

SJP002 Placebo 2

1 drop q.i.d for 12 weeks

Trial Locations (1)

Unknown

Seoul St. Mary's Hospital, Seoul

All Listed Sponsors

lead

Samjin Pharmaceutical Co., Ltd.

INDUSTRY

NCT03723811 - Clinical Study to Investigate the Efficacy and Safety of SJP002 Ophthalmic Solution in Patients With Dry Eye Syndrome. | Biotech Hunter | Biotech Hunter